Text Size

Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma

This study has been completed.
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01266343
First received: December 22, 2010
Last updated: December 23, 2010
Last verified: December 2010
History of Changes
  Purpose

The investigators wanted to reported the results of immediate anterior chamber paracentesis (ACP), compared to Mannitol infusion, in patients with acute primary angle-closure glaucoma (PACG). In this study, the investigators first divided patients into three sub-groups according to their initial intraocular pressure (IOP) for analyzing the differences of IOP control, severity of corneal edema, waiting time for laser peripheral iridotomy (LPI), and visual outcome between ACP and Mannitol infusion.


Condition
Glaucoma
Acute Primary Angle-closure Glaucoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
Drug Information available for: Mannitol
U.S. FDA Resources

Further study details as provided by Taipei Medical University WanFang Hospital:

Enrollment: 60
Study Start Date: January 2007
Study Completion Date: December 2009
Groups/Cohorts
Experimental Group
Control Group

Detailed Description:

The investigators demonstrated that ACP could be first considered in patients with initial IOP between 45 to 60 mmHg because it provided better visual outcome than Mannitol infusion through the rapid stabilization of the anterior segment, which was achieved by rapid IOP control, better corneal edema regression, shortening waiting time for LPI. However, ACP should be considered in patients with the initial IOP of 60mmHg and higher only when Mannitol was contraindicated.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Glaucoma patients

Criteria

Inclusion Criteria:

  • first attack of acute PACG;
  • initial presenting IOP was higher than 45 mmHg;
  • diagnosis confirmed by gonioscopic examination;
  • patients within 48 hours of symptom onset.

Exclusion Criteria:

  • been incompletely followed up within 2 weeks;
  • been using anti-glaucomatous medication before ACP or Mannitol infusion;
  • previous intraocular surgeries on the same eye;
  • contraindication for Mannitol;
  • history of other vision-threatening ocular diseases.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01266343

Locations
Taiwan
Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Hui-Chun Ho Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Hui-Chun Ho, Department of Ophthalmology, Wanfang Hospital
ClinicalTrials.gov Identifier: NCT01266343     History of Changes
Other Study ID Numbers: 99018
Study First Received: December 22, 2010
Last Updated: December 23, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
Glaucoma
anterior chamber paracentesis
conventional Mannitol infusion

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Angle-Closure
Acute Disease
Ocular Hypertension
Eye Diseases
Disease Attributes
Pathologic Processes
Mannitol
 Diuretics, Osmotic
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 17, 2013